Publication details

Průběžná zpráva o klinickém hodnocení léčiva RASmiR 01.08.2022 – 31.07.2023

Title in English Interim Report on Clinical Drug Evaluation RASmiR 01.08.2022 – 31.07.2023
Authors

DEMLOVÁ Regina

Year of publication 2023
Web RASMIR
Description Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) Phase II. This is the fourth annual DSUR for the RASmiR trial summarising safety data received by the Sponsor from August 1, 2022 – July 31, 2023. Clinical trial RASmiR is a multicenter, open label, single-arm, phase II trial. During the period under review, 30 patients were enrolled to the study.

You are running an old browser version. We recommend updating your browser to its latest version.

More info